AACP
HAE icon

Advantage Alpha Capital Partners’s Haemonetics HAE Stock Holding History

Advantage Alpha Capital Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-36,536
Closed -$4.34M – 132
2020
Q4 		$4.34M Sell
36,536
-54,710
-60% -$5.89M 0.95% 52
2020
Q3 		$7.96M Sell
91,246
-8,924
-9% -$780K 1.84% 9
2020
Q2 		$8.97M Buy
100,170
+74,352
+288% +$7.51M 2.1% 1
2020
Q1 		$2.57M Buy
+25,818
New +$2.8M 0.92% 54

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advantage Alpha Capital Partners's HAE Position: Q1 2021 in Review

Advantage Alpha Capital Partners sold out of Haemonetics (HAE) in Q1 2021, closing a stake of 36,536 shares — an estimated $4.34M sold.

Advantage Alpha Capital Partners first reported a position in HAE in Q1 2020 and held it in 4 quarters. The position peaked at $8.97M in Q2 2020. 296 funds tracked by Wall St. Rank hold HAE as of Q1 2021.

  • Advantage Alpha Capital Partners reported no remaining Haemonetics position as of Q1 2021 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 36,536 Haemonetics shares in Q1 2021, an estimated $4.34M.
  • Advantage Alpha Capital Partners first reported a position in Haemonetics in Q1 2020 and held it in 4 quarters.
  • Advantage Alpha Capital Partners's Haemonetics position peaked at $8.97M in Q2 2020.
  • 296 funds tracked by Wall St. Rank held Haemonetics as of Q1 2021.

Based on Advantage Alpha Capital Partners's 13F filing for Q1 2021, filed 13 May 2021.